News

Under the deal, Reckitt will be granted exclusive worldwide rights for the development and commercialization of XenoPort’s arbaclofen placarbil for all indications. Arbaclofen placarbil is a patent protected

The supply and distribution agreement was first agreed to by the companies in November 2010 and is due to expire on 31 December 2014. As part of the

The company will provide its lead cell permeable peptide targeting inflammatory diseases to Dr. Robert Nussenblatt to investigate its efficacy in animal models of uveitis. Portage will also

The company also secured final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for

EjectDelay’s active ingredient is a fast absorbing and vanishing gel formulation with the active drug benzocaine at 7.5% designed to reduce transfer to the partner. A total of

The transaction will provide Ohr Pharmaceutical with a proprietary, patent protected, sustained release technology platform under development as well as a pipeline of pre-clinical sustained release drug product

Donnatal is available in two formulations: immediate release Donnatal Tablets, and immediate release Donnatal Elixir, a fast acting liquid. For decades, Donnatal has delivered gentle relief from the

OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in eight patent families. The newly granted US patents have numbers 8,486,389 and 8,545,836.

BRF funding will expand that study to evaluate whether the "dose" of physical activity predicts the magnitude of response. "The early studies across the neuroscience community do indicate